Ralph Petri named to Kerr’s board
RALEIGH, N.C. Kerr Drug pharmacy veteran Ralph Petri has been appointed to the company’s board of directors following more than a decade of senior management service with the regional chain innovator.
Petri serves as executive vice president of pharmacy and supply chain operations for Kerr. His long career in retail pharmacy includes a 28-year career with the former Thrift Drug, where he rose to vice president of merchandise and distribution. After that Pittsburgh-based chain bought Rome, N.Y.-based Fay’s Drug in 1996, Petri became senior vice president of the newly acquired company. Petri was serving as Vice President of Merchandise for the Eckerd Corp.—a position he assumed in the wake of the Thrift/Eckerd merger—when he returned to the newly formed Kerr Drug in 1997, rejoining former Thrift colleagues led by Kerr’s current chairman, president and chief executive officer, Tony Civello.
“Ralph carries with him many, many years of broad-based experience in drug stores,” said Civello. “His tenure in the merchandising and pharmacy business has made his contributions invaluable.
“He is widely-admired and respected in the industry,” added Kerr’s top executive. “Old-timers and newcomers alike admire not only his brilliant strategic thinking but his cordiality. He will add new dimension to the board’s direction.”
FDA grants orphan drug status to two non-Hodgkin’s lymphoma drugs
AMSTERDAM, Netherlands The Food and Drug Administration has granted orphan drug designations to Kiadis Pharma’s drug Reviroc for two types of non-Hodgkin’s lymphoma, Kiadis announced Monday.
The FDA granted one designation for diffuse large B-cell lymphoma and one for follicular lymphoma. The drug is under development for the elimination of cancer cells from an autologous graft in bone marrow transplants for end-stage blood cancer patients.
“This is an important strategic milestone in the development of Reviroc, and we are very pleased with the orphan drug designations received from the FDA,” Kiadis chief executive officer Manja Bouman said in a statement.
The FDA gives orphan drug designations to drugs developed for treating diseases and conditions affecting fewer than 200,000 people in the United States. The designation allows for accelerated review, tax benefits, exemption from user fees and a seven-year period of market exclusivity in the U.S. after regulatory approval.
FDA approves Boostrix vaccine for use in adults
NEW YORK The Food and Drug Administration has approved a booster vaccine for use in adults, manufacturer GlaxoSmithKline announced Monday.
GSK developed the vaccine, Boostrix (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed), for use in patients aged 10 to 18 as a protection against tetanus, diphtheria and whooping cough; the FDA’s new approval allows for its use in patients aged 19 to 64 as well.
The new approval follows two clinical trials of 3,000 adult patients.
Sanofi-Aventis makes a similar vaccine, Adacel, for use in patients aged 11 to 64.